Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease
ABSTRACT Background: non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries. Lifestyle changes are the pillar of the treatment, although a pharmacological approach is sometimes required in the case of a failure to respond/adhere to the di...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aran Ediciones
2018-10-01
|
| Series: | Revista Espanola de Enfermedades Digestivas |
| Subjects: | |
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018001000006&tlng=en |
| _version_ | 1798020617446883328 |
|---|---|
| author | Rocío Aller Cristina Laserna Miguel-Ángel Rojo Natalia Mora Concepción García María Pina Rebeca Sigüenza Miguel Durà David Primo Olatz Izaola Daniel-A. De-Luis |
| author_facet | Rocío Aller Cristina Laserna Miguel-Ángel Rojo Natalia Mora Concepción García María Pina Rebeca Sigüenza Miguel Durà David Primo Olatz Izaola Daniel-A. De-Luis |
| author_sort | Rocío Aller |
| collection | DOAJ |
| description | ABSTRACT Background: non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries. Lifestyle changes are the pillar of the treatment, although a pharmacological approach is sometimes required in the case of a failure to respond/adhere to the diet. Objective: the aim of this study was to evaluate the effect of silymarin and the influence of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant on the response to treatment in patients with NAFLD in a pilot study. Methods: a total of 54 patients with a NAFLD proven biopsy were enrolled in an open prospective study and were treated with Eurosil 85(r) (silymarin + vitamin E) for six months. Biochemical parameters and cardiovascular risk factors (diabetes mellitus, dyslipidemia, hypertriglyceridemia, arterial hypertension and HOMA-IR > 2.5) were recorded before and after six months of treatment. Non-invasive indexes (fatty liver index, lipid accumulation product and NAFLD-fibrosis score) were also calculated. The rs738409 PNPLA3 gene polymorphism status was also determined. Results: significant statistical changes from baseline values after six months of treatment were observed in transaminases levels but not in non-invasive index markers. Twenty patients (37.1%) were G allele carriers and had a higher percentage of lobular inflammation and ballooning on the basal liver biopsy. Patients with the G allele had a smaller decrease in transaminases levels after treatment with silymarin + vitamin E than non-G-allele carriers. Conclusions: treatment with silymarin + vitamin E produced a decrease in transaminases after six months of treatment without an accompanying weight loss. PNPLA3 G-allele carriers responded poorly to the treatment. |
| first_indexed | 2024-04-11T17:00:23Z |
| format | Article |
| id | doaj.art-a0f1260c716043c4a338a80ed87cbe24 |
| institution | Directory Open Access Journal |
| issn | 1130-0108 |
| language | English |
| last_indexed | 2024-04-11T17:00:23Z |
| publishDate | 2018-10-01 |
| publisher | Aran Ediciones |
| record_format | Article |
| series | Revista Espanola de Enfermedades Digestivas |
| spelling | doaj.art-a0f1260c716043c4a338a80ed87cbe242022-12-22T04:13:10ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01082018-10-011101063464010.17235/reed.2018.5602/2018Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver diseaseRocío AllerCristina LasernaMiguel-Ángel RojoNatalia MoraConcepción GarcíaMaría PinaRebeca SigüenzaMiguel DuràDavid PrimoOlatz IzaolaDaniel-A. De-LuisABSTRACT Background: non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries. Lifestyle changes are the pillar of the treatment, although a pharmacological approach is sometimes required in the case of a failure to respond/adhere to the diet. Objective: the aim of this study was to evaluate the effect of silymarin and the influence of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant on the response to treatment in patients with NAFLD in a pilot study. Methods: a total of 54 patients with a NAFLD proven biopsy were enrolled in an open prospective study and were treated with Eurosil 85(r) (silymarin + vitamin E) for six months. Biochemical parameters and cardiovascular risk factors (diabetes mellitus, dyslipidemia, hypertriglyceridemia, arterial hypertension and HOMA-IR > 2.5) were recorded before and after six months of treatment. Non-invasive indexes (fatty liver index, lipid accumulation product and NAFLD-fibrosis score) were also calculated. The rs738409 PNPLA3 gene polymorphism status was also determined. Results: significant statistical changes from baseline values after six months of treatment were observed in transaminases levels but not in non-invasive index markers. Twenty patients (37.1%) were G allele carriers and had a higher percentage of lobular inflammation and ballooning on the basal liver biopsy. Patients with the G allele had a smaller decrease in transaminases levels after treatment with silymarin + vitamin E than non-G-allele carriers. Conclusions: treatment with silymarin + vitamin E produced a decrease in transaminases after six months of treatment without an accompanying weight loss. PNPLA3 G-allele carriers responded poorly to the treatment.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018001000006&tlng=enNon-alcoholic fatty liver diseaseSilymarinLiver biopsyPNPLA3 |
| spellingShingle | Rocío Aller Cristina Laserna Miguel-Ángel Rojo Natalia Mora Concepción García María Pina Rebeca Sigüenza Miguel Durà David Primo Olatz Izaola Daniel-A. De-Luis Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease Revista Espanola de Enfermedades Digestivas Non-alcoholic fatty liver disease Silymarin Liver biopsy PNPLA3 |
| title | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease |
| title_full | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease |
| title_fullStr | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease |
| title_full_unstemmed | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease |
| title_short | Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease |
| title_sort | role of the pnpla3 polymorphism rs738409 on silymarin vitamin e response in subjects with non alcoholic fatty liver disease |
| topic | Non-alcoholic fatty liver disease Silymarin Liver biopsy PNPLA3 |
| url | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018001000006&tlng=en |
| work_keys_str_mv | AT rocioaller roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT cristinalaserna roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT miguelangelrojo roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT nataliamora roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT concepciongarcia roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT mariapina roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT rebecasiguenza roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT migueldura roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT davidprimo roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT olatzizaola roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease AT danieladeluis roleofthepnpla3polymorphismrs738409onsilymarinvitamineresponseinsubjectswithnonalcoholicfattyliverdisease |